Development of a novel therapy for inflammatory bowel disease by oral administration of DNA vaccine expressing suppressor of cytokine signaling.

免疫反应失衡导致免疫疾病。细胞因子信号抑制因子（SOCS）在免疫应答中起着重要的调节作用。为了评估SOCS DNA疫苗作为一种治疗策略的有效性，我们使用dss诱导的结肠炎小鼠模型来评估临床评估。此外，我们还研究了戊型肝炎病毒样颗粒（HEV-VLPs）是否可以作为SOCS DNA的粘膜疫苗载体并刺激粘膜。我们可以提供一种方法来开发一种新的治疗性口服疫苗策略来治疗粘膜炎症。在这项研究中，我们研究了SOCS在小鼠葡聚糖硫酸钠（DSS）诱导的结肠炎（一种类似人类IBD的结肠炎模型）发展中的作用。DSS治疗的SOCS3小鼠结肠炎的发生明显减少，而SOCS1小鼠则没有。此外，与腹腔注射SOCS3 DNA疫苗相比，口服SOCS3 DNA疫苗包封的VLP可有效抑制dss诱导结肠炎的发生。我们发现口服疫苗的新策略将导致新的免疫疗法可用于诱导粘膜免疫反应。

Imbalance of immune responses cause immune diseases. Suppressor of cytokine signaling (SOCS) plays a crucial regulatory role in immune response. To assess effectiveness the SOCS DNA vaccine as a therapeutic strategy, we evaluate the clinical assessments using the mouse model of DSS-induced colitis. In addition, We investigate whether hepatitis E virus-like particles (HEV-VLPs) could be utilized as a mucosal vaccine carrier vehicle for SOCS DNA and to stimulate mucosal. We may provide a means to developing a new therapeutic oral vaccination strategy for treating mucosal inflammation. In this study, we investigated the role of SOCS in the development of murine dextran sulfate sodium(DSS)-induced colitis, a model of colitis resembling human IBD. Development of colitis was significantly reduced in SOCS3, but not SOCS1, DNA injected mice treated with DSS. Moreover, SOCS3-DNA vaccine-encapsulated VLP oral administration is involved in suppression of the development of DSS-induced colitis efficiently compared with intraperitoneally injection of SOCS3 DNA vaccine. We found that our novel strategies by oral vaccine administration will lead up to new immune therapies available for induction of mucosal immune responses.